Biotech Profile
Ocugen – Targeting 300,000 RP Patients with Gene-Agnostic Modifier Therapy Platform
Pennsylvania biotech Ocugen advances a modifier gene therapy approach that resets retinal cellular networks rather than replacing individual mutations, positioning OCU400 to address up to 300,000 RP patients in the U.S. and Europe—far beyond the 1-2% eligible for current mutation-specific
4 November 2025